Merit Medical Systems (NASDAQ:MMSI) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Merit Medical Systems (NASDAQ:MMSI) released its earnings results on Tuesday. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.08, FiscalAI reports. Merit Medical Systems had a net margin of 8.02% and a return on equity of 14.27%. The company had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems updated its FY 2026 guidance to 4.010-4.150 EPS.

Merit Medical Systems Stock Performance

Merit Medical Systems stock traded up $0.82 during mid-day trading on Tuesday, reaching $82.43. 1,038,414 shares of the company’s stock were exchanged, compared to its average volume of 732,739. The business’s fifty day simple moving average is $84.17 and its 200 day simple moving average is $85.01. The firm has a market capitalization of $4.89 billion, a PE ratio of 42.27, a P/E/G ratio of 2.23 and a beta of 0.61. The company has a quick ratio of 2.86, a current ratio of 4.28 and a debt-to-equity ratio of 0.48. Merit Medical Systems has a one year low of $77.62 and a one year high of $107.27.

Institutional Trading of Merit Medical Systems

Several hedge funds and other institutional investors have recently bought and sold shares of MMSI. AQR Capital Management LLC boosted its position in Merit Medical Systems by 7.3% during the 1st quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after acquiring an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock worth $76,039,000 after purchasing an additional 103,878 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Merit Medical Systems by 745.9% during the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 813 shares during the period. First Trust Advisors LP raised its position in shares of Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock valued at $5,535,000 after purchasing an additional 11,770 shares during the period. Finally, Cerity Partners LLC boosted its stake in Merit Medical Systems by 9.1% in the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock worth $282,000 after purchasing an additional 251 shares during the period. Institutional investors own 99.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on MMSI shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Merit Medical Systems in a research note on Monday, December 29th. Robert W. Baird set a $108.00 price objective on shares of Merit Medical Systems in a research note on Tuesday, December 16th. Wells Fargo & Company cut their target price on Merit Medical Systems from $103.00 to $95.00 and set an “overweight” rating for the company in a research report on Friday, November 14th. Piper Sandler decreased their price objective on Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a research note on Wednesday, February 18th. Finally, BTIG Research started coverage on shares of Merit Medical Systems in a research report on Friday, February 6th. They set a “buy” rating and a $107.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $105.67.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.